Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing

Authors

Alexandra Zara Rozalen, Department of Pathology, Veterans Affairs Medical Center, Washington, DC 20422, USA.
Jose Manuel Martin, Department of Pathology, Veterans Affairs Medical Center, Washington, DC 20422, USA.
Rithika Rajendran, Department of Pathology, Veterans Affairs Medical Center, Washington, DC 20422, USA.
Maneesh Jain, Section of Hematology & Oncology, Veterans Affairs Medical Center, Washington, DC 20422, USA.
Victor E. Nava, Department of Pathology, Veterans Affairs Medical Center, Washington, DC 20422, USA.

Document Type

Journal Article

Publication Date

3-19-2024

Journal

Current oncology (Toronto, Ont.)

Volume

31

Issue

3

DOI

10.3390/curroncol31030118

Keywords

ductal adenocarcinoma; genetic mutations; next-generation sequencing; prostate cancer

Abstract

Ductal adenocarcinoma of the prostate (DAP) is an uncommon variant of prostate cancer associated with aggressive disease and poor outcome. It presents most frequently as a mixed tumor combined with acinar adenocarcinoma. Although the histopathological features of DAP are well known, its genomic characteristics are still evolving, prompting the suggestion that all DAP would benefit from molecular analysis with the purpose of improving tumor recognition, genetic classification, and, ultimately, personalized therapy. Herein, we report a case of DAP with novel genetic alterations (BCOR P1153S, ERG M219I, KDR A750E, POLE S1896P, and RAD21 T461del).

APA Citation

Zara Rozalen, Alexandra; Martin, Jose Manuel; Rajendran, Rithika; Jain, Maneesh; and Nava, Victor E., "Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing" (2024). GW Authored Works. Paper 4502.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/4502

Department

Pathology